Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML
G. Pianigiani, A. Gagliardi, F. Mezzasoma, F. Rocchio, V. Tini, B. Bigerna, P. Sportoletti, S. Caruso, A. Marra, G. Spinozzi, S. Shacham, Y. Landesman, C. Quintarelli, F. Locatelli, M. P. Martelli, , L. Brunetti
This study shows that prolonged XPO1 inhibition is more effective than intermittent dosing in NPM1-mutated AML by achieving stable HOX downregulation and anti-leukemic activity.
bioRxiv · Dec 11, 2021 · PreprintCancer Biology